F-Prime's Ben Aus­pitz co-leads $30M Se­ries A with Or­biMed for his lat­est rare dis­ease ven­ture

Hav­ing spent his 13 years at F-Prime Part­ners back­ing and ad­vis­ing rare dis­ease com­pa­nies — in­clud­ing Di­men­sion Ther­a­peu­tics and Or­chard Ther­a­peu­tics, which he co-found­ed — Ben Aus­pitz …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER